Most Popular Stories
- Ben Venue can't say when crucial cancer drug will be available
- Gene study finds tumor-cell flaw possibly vulnerable to Pfizer, AZ cancer meds
- Ben Venue's idled plant triggers 'dire' leukemia-drug shortage
- The best of times, the worst of times?
- Novartis dealt another setback to broader Menveo use
- Pioneering stem cell therapy mends damaged heart tissue in patients
- Karo Bio walks away from Phase III cholesterol drug due to safety risks
- Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix
- Pioneering stem cell therapy mends damaged heart tissue in patients
- GSK studies Chinese remedies to discover new drugs
- Chelsea shares nosedive on FDA's questions about key drug
Webinars
- Webinar: Next Gen Sequencing from FFPE SamplesNext generation sequencing (NGS) technologies hold enormous promise to advance personalize
- Getting the most out of First-in-Human and Early Clinical TrialsIn a follow-up to our webinar last month on first-in-human drug studies, FierceBiotech edi
- Active Directory & the Cloud for Biotech & PharmaBiotech and pharmaceutical companies are leaders cloud/SaaS technology adoption. This webi
- Special Studies in Cancer Patients: AME and Cardiac SafetyFierceBiotech Editor John Carroll will moderate an expert panel discussion exploring how c
Featured Jobs
-
Facilities Project Manager
Genomics Institute of the Novartis Research Foundation - San Diego, CA -
Manager, Business Development
Clinical Resource Network - Chicago, IL -
District Sales Manager – Hematology, Denver / Phoenix Job
Celgene Corporation - Denver, CO, US -
Product Manager, Channel Marketing Job
Celgene Corporation - Summit, NJ, US -
Manager Business Development
Clinical Resource Network - US West Coast
Events
- World Orphan Drug Congress USA 2012
10-13 April, 2012 — Gaylord National Resort and Convention Center, Washington, D.C. - Just Released: New Trends in Preventive and Therapeutic Vaccine
- DCAT Week '12 Biologics Forum & Networking Reception
Mar 14 — New York City - CALBIO2012: Driven By Patients - Marriott Marquis
March 8-9 — San Francisco, CA
Free Newsletter
FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 90,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!
Popular Topics
Whitepapers
- The Top 10 Biotechnology Companies: Positioning, performance and SWOT analyses
- The Cutting Edge of Chemistry
- API in Capsule: Common "First in Man" approaches vs. The Lost Art of Formulation Development
- Central Nervous System (CNS) Compound Library from OTAVA
- The 3W Gaurrantee: What you Really Saved when you invest in Outsourced Talent
- Niche Tourism Beginning and digital marketing : Beginning of the future?
David Goldstein
David Goldstein, geneticist and director of Duke University's Center for Population Genomics and Pharmacogenetics
